CY1105795T1 - Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων - Google Patents
Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακωνInfo
- Publication number
- CY1105795T1 CY1105795T1 CY20061101680T CY061101680T CY1105795T1 CY 1105795 T1 CY1105795 T1 CY 1105795T1 CY 20061101680 T CY20061101680 T CY 20061101680T CY 061101680 T CY061101680 T CY 061101680T CY 1105795 T1 CY1105795 T1 CY 1105795T1
- Authority
- CY
- Cyprus
- Prior art keywords
- orally administered
- bioavailability
- formulations
- improving
- administered drugs
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 abstract 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Μια μέθοδος αύξησης της συστηματικής έκθεσης κυττάρων που επιλέγονται από καρκινικά κύτταρα και φυσιολογικά κύτταρα σε μια χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, όπου ένας βιοενισχυτής που περιέχει έναν αναστολέα της προκαλούμενης από και/ή σχετιζόμενης με BCRP μεταφοράς φαρμάκων χορηγείται από το στόμα συγχρόνως με την αναφερόμενη χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, και στην οποία μέθοδο ο αναστολέας χορηγείται συγχρόνως με την φαρμακευτική ένωση.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1012066 | 1999-05-17 | ||
NL1012481 | 1999-06-30 | ||
PCT/NL2000/000331 WO2000069390A2 (en) | 1999-05-17 | 2000-05-17 | Compositions for improving bioavailability of orally administered drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105795T1 true CY1105795T1 (el) | 2011-02-02 |
Family
ID=26642978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101680T CY1105795T1 (el) | 1999-05-17 | 2006-11-16 | Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων |
Country Status (10)
Country | Link |
---|---|
US (2) | US7030132B2 (el) |
EP (2) | EP1749540B1 (el) |
AT (2) | ATE484295T1 (el) |
AU (1) | AU4955200A (el) |
CY (1) | CY1105795T1 (el) |
DE (2) | DE60030283T2 (el) |
DK (1) | DK1189637T3 (el) |
ES (1) | ES2270834T3 (el) |
PT (1) | PT1189637E (el) |
WO (1) | WO2000069390A2 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
EP1749540B1 (en) * | 1999-05-17 | 2010-10-13 | Cancer Research Ventures Limited | Compositions for improving bioavailability of orally administered drugs |
HU0100947D0 (en) * | 2001-03-02 | 2001-05-28 | Solvo Kft | Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers |
US7169763B2 (en) * | 2002-02-22 | 2007-01-30 | Oliver Yoa-Pu Hu | Cytochrome P450 3A inhibitors and enhancers |
RU2007103703A (ru) * | 2004-07-01 | 2008-08-10 | Дзе Недзеландз Кэнсе Инститьют (Nl) | Комбинация, включающая ингибитор бррм (белка резистентности рака молочной железы) и 4-(4-метилпиперазин-1-илметил)-n-(4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил)-бензамид |
CN101010114B (zh) | 2004-08-27 | 2010-05-26 | 皇家飞利浦电子股份有限公司 | 电子遥控药丸和用于供应至少一种药物的*** |
JP2008521794A (ja) * | 2004-11-29 | 2008-06-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム |
WO2006065125A1 (en) * | 2004-12-16 | 2006-06-22 | Het Nederlands Kanter Instituut | Means and methods for determining and/or influencing transportation |
WO2009083042A1 (en) * | 2007-12-31 | 2009-07-09 | Olaf Van Tellingen | Methods and means for the treatment of cancer |
CN101945613B (zh) * | 2008-02-18 | 2014-08-13 | 皇家飞利浦电子股份有限公司 | 为患者用药 |
JP5681861B2 (ja) * | 2008-03-31 | 2015-03-11 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | センサを有する嚥下型カプセルを作成する方法 |
JP5627569B2 (ja) | 2008-04-30 | 2014-11-19 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドSiemens Medical Solutions USA,Inc. | 新規基質に基づくpet造影剤 |
CN102065930B (zh) * | 2008-06-19 | 2013-05-22 | 皇家飞利浦电子股份有限公司 | 用于在潮湿环境下传递粉末状药物的装置 |
CN102076375B (zh) * | 2008-06-25 | 2013-11-20 | 皇家飞利浦电子股份有限公司 | 包括多个药物储存器的电子药丸 |
US10046109B2 (en) | 2009-08-12 | 2018-08-14 | Progenity, Inc. | Drug delivery device with compressible drug reservoir |
CN106432490B (zh) * | 2016-09-14 | 2020-01-07 | 北京大学 | 一种abcg2单克隆抗体及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201084A (en) | 1982-06-25 | 1985-10-11 | New Zealand Dev Finance | 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such |
CZ283038B6 (cs) | 1991-01-11 | 1997-12-17 | Laboratoires Glaxo Sa | Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem |
WO1994001408A1 (en) | 1992-07-10 | 1994-01-20 | Laboratoires Glaxo S.A. | Anilide derivatives |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
BR9509251A (pt) | 1994-10-05 | 1997-10-21 | Glaxo Wellcome Inc | Composição farmacêutica processo de reverte reduzir ou inibir a resistência a multidrogas ou de restaurar a sensibilidade de um tumor e artigo manufaturado |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
GB9710612D0 (en) * | 1997-05-23 | 1997-07-16 | Glaxo Group Ltd | Synthesis of acridine derivatives |
BR9809694A (pt) | 1997-05-27 | 2000-10-03 | Baker Norton Pharma | Processo e composição para administração de taxanos oralmente a pacientes humanos |
GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
DE69935782T3 (de) * | 1998-02-05 | 2017-01-05 | University Of Maryland, Baltimore | Brustkrebsresistenzprotein (BCRP) und für dieses kodierende DNA |
AU764370B2 (en) | 1998-06-18 | 2003-08-14 | George Washington University, The | Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects |
DK1102594T3 (da) | 1998-08-05 | 2002-08-26 | Aventis Pharma Sa | Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin |
EP1749540B1 (en) * | 1999-05-17 | 2010-10-13 | Cancer Research Ventures Limited | Compositions for improving bioavailability of orally administered drugs |
US6521635B1 (en) * | 2000-01-20 | 2003-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of MXR transport by acridine derivatives |
-
2000
- 2000-05-17 EP EP06117838A patent/EP1749540B1/en not_active Expired - Lifetime
- 2000-05-17 EP EP00931720A patent/EP1189637B1/en not_active Expired - Lifetime
- 2000-05-17 AT AT06117838T patent/ATE484295T1/de not_active IP Right Cessation
- 2000-05-17 DE DE60030283T patent/DE60030283T2/de not_active Expired - Lifetime
- 2000-05-17 PT PT00931720T patent/PT1189637E/pt unknown
- 2000-05-17 ES ES00931720T patent/ES2270834T3/es not_active Expired - Lifetime
- 2000-05-17 AT AT00931720T patent/ATE337016T1/de active
- 2000-05-17 AU AU49552/00A patent/AU4955200A/en not_active Abandoned
- 2000-05-17 DE DE60045114T patent/DE60045114D1/de not_active Expired - Lifetime
- 2000-05-17 WO PCT/NL2000/000331 patent/WO2000069390A2/en active IP Right Grant
- 2000-05-17 DK DK00931720T patent/DK1189637T3/da active
-
2001
- 2001-11-19 US US09/988,285 patent/US7030132B2/en not_active Expired - Fee Related
-
2006
- 2006-01-30 US US11/341,524 patent/US20060128743A1/en not_active Abandoned
- 2006-11-16 CY CY20061101680T patent/CY1105795T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60045114D1 (de) | 2010-11-25 |
EP1749540A3 (en) | 2007-05-30 |
EP1189637A2 (en) | 2002-03-27 |
DE60030283D1 (de) | 2006-10-05 |
ATE337016T1 (de) | 2006-09-15 |
WO2000069390A3 (en) | 2001-12-13 |
US7030132B2 (en) | 2006-04-18 |
US20060128743A1 (en) | 2006-06-15 |
AU4955200A (en) | 2000-12-05 |
EP1749540A2 (en) | 2007-02-07 |
EP1749540B1 (en) | 2010-10-13 |
ATE484295T1 (de) | 2010-10-15 |
DK1189637T3 (da) | 2006-12-11 |
DE60030283T2 (de) | 2007-09-20 |
EP1189637B1 (en) | 2006-08-23 |
PT1189637E (pt) | 2007-01-31 |
ES2270834T3 (es) | 2007-04-16 |
WO2000069390A2 (en) | 2000-11-23 |
US20020128282A1 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105795T1 (el) | Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων | |
CY1118873T1 (el) | Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης | |
CY1106727T1 (el) | Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων | |
CY1106072T1 (el) | Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος | |
TR200102226T2 (tr) | Formoterol ve bir tiotropium tuzunun kombinasyonları | |
CY1112562T1 (el) | Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης | |
SE0003449D0 (sv) | Anticancer compositions | |
AR023972A1 (es) | Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos | |
ECSP045411A (es) | Derivados de quinolinona | |
BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
AR021981A1 (es) | Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero | |
TR199800631A2 (xx) | Ecza form�lasyonu. | |
DE60137960D1 (de) | Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva | |
CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
CY1107465T1 (el) | Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων | |
ATE292453T1 (de) | Antivirale arznei | |
TR199900336T2 (xx) | EAA antagonistleri olarak tetrahidrokinolin t�revleri. | |
EA200401227A1 (ru) | Система доставки лекарства с контролируемым высвобождением, включающая правастатин | |
TR199800765T2 (xx) | Otoim�n hastal�klar�n tedavisine mahsus bir farmas�tik bile�im | |
EA200701409A1 (ru) | Новая композиция | |
DK1152763T3 (da) | Anvendelse af desozypeganin til behandling af stofafhængighed | |
AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
SE9902742D0 (sv) | New pharmaceutical formultion | |
ITMI992736A0 (it) | Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi | |
DE10293092D2 (de) | Schilddrüsentherapeutika |